Roivant Sciences (NASDAQ:ROIV) Price Target Increased to $18.00 by Analysts at HC Wainwright

Roivant Sciences (NASDAQ:ROIVFree Report) had its price objective lifted by HC Wainwright from $17.00 to $18.00 in a research note published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also recently commented on ROIV. TheStreet raised Roivant Sciences from a d rating to a c+ rating in a research note on Tuesday, February 13th. Bank of America upped their target price on Roivant Sciences from $11.00 to $12.00 and gave the company a neutral rating in a research note on Tuesday, January 2nd. Deutsche Bank Aktiengesellschaft initiated coverage on Roivant Sciences in a research note on Tuesday, December 12th. They set a buy rating and a $14.00 target price on the stock. Piper Sandler initiated coverage on Roivant Sciences in a research note on Friday, January 5th. They issued an overweight rating and a $20.00 price objective on the stock. Finally, Wolfe Research initiated coverage on Roivant Sciences in a research note on Thursday, February 15th. They issued an outperform rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $16.90.

Read Our Latest Research Report on Roivant Sciences

Roivant Sciences Trading Up 5.4 %

Shares of ROIV stock opened at $11.51 on Wednesday. Roivant Sciences has a 1 year low of $6.97 and a 1 year high of $13.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. The stock’s 50 day simple moving average is $10.78 and its two-hundred day simple moving average is $10.36. The company has a market cap of $9.28 billion, a PE ratio of 2.21 and a beta of 1.34.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The firm had revenue of $37.14 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. Research analysts predict that Roivant Sciences will post -1.36 earnings per share for the current year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the sale, the chief operating officer now owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.60% of the company’s stock.

Institutional Trading of Roivant Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of ROIV. Bank of New York Mellon Corp boosted its position in Roivant Sciences by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 47,274 shares of the company’s stock valued at $233,000 after acquiring an additional 4,335 shares in the last quarter. Citigroup Inc. lifted its holdings in shares of Roivant Sciences by 1,803.6% during the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after purchasing an additional 5,447 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Roivant Sciences by 3.0% during the 1st quarter. BlackRock Inc. now owns 4,044,419 shares of the company’s stock valued at $19,980,000 after purchasing an additional 117,329 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 13.8% during the 1st quarter. Vanguard Group Inc. now owns 1,319,499 shares of the company’s stock valued at $6,519,000 after purchasing an additional 159,787 shares during the last quarter. Finally, American International Group Inc. purchased a new stake in shares of Roivant Sciences during the 1st quarter valued at $8,965,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.